The role of the hepatitis B virus protein HBx in liver cell proliferation and apoptosis remains controversial. Using a transgenic mouse model, we have recently shown that HBx stimulates the apoptotic turnover of hepatocytes, independently of p53. In this paper, we tested whether the proapoptotic function of HBx can interfere with Bcl-2 during hepatic apoptosis in vivo. HBx transgenic mice were crossed with PK-hBcl-2 mice that are protected against Fas killing by constitutive overexpression of Bcl-2 in hepatocytes. In a lethal challenge with Fas antibodies, HBx expressed at low levels restored sensitivity to Fas-mediated apoptosis and fulminant hepatic failure in mice overexpressing Bcl-2. Furthermore, cytochrome c release from mitochondria and caspase 3 activation were restored to normal levels in HBx/Bcl-2 mice during transduction of the Fas signal. Thus, the proapoptotic activity of HBx overcomes or bypasses the inhibitory eect of Bcl-2 against Fas cytotoxicity. This eect was not apparently mediated through downregulation of the PK-hBcl-2 transgene or via delocalization of the Bcl-2 protein, and a direct interaction of HBx with Bcl-2, Bcl-X L or Bax could not be evidenced in yeast two-hybrid assays. We further show that apoptosis induced by ectopic expression of HBx is associated with mitochondrial membrane alterations and caspase 3 activation. Our data indicate that the dominant function of HBx upon Bcl-2-regulated control of apoptosis might play an important role in the pathogenesis of chronic hepatitis B.
Introduction
The hepatitis B virus (HBV) is a small hepatotropic DNA virus responsible for acute and chronic liver disease worldwide. Based on epidemiological data, it has been demonstrated that HBV plays a major role in the development of human hepatocellular carcinoma (HCC) (Beasley et al., 1981) , but the molecular basis for the oncogenic activity of this virus remains elusive (for review, see Buendia, 1992) . The HBV genome encodes a regulatory protein named HBx which harbors weak transcriptional transactivation activity on a variety of viral or cellular promoters, both in vivo and in vitro (Balsano et al., 1993; Twu and Schloemer, 1987) . In the absence of direct binding to dsDNA, HBx might stimulate transcription via protein ± protein interactions in the nucleus or by activating signal transduction pathways from a cytoplasmic location (Yen, 1996) .
HBx has been implicated in HBV pathogenesis and in cancer development by its ability to deregulate cell cycle check points, to activate the expression of some oncogenes and in¯ammatory cytokines, and to induce liver tumors in a transgenic mouse strain (Benn and Schneider, 1995; Kim et al., 1991; Lara-Pezzi et al., 1998) . In other transgenic models, HBx expression has no obvious pathological eect, but it sensitizes liver cells to carcinogenic treatments and it co-operates with c-myc in accelerating liver carcinogenesis (Slagle et al., 1996; Terradillos et al., 1997) . Importantly, a number of studies in dierent experimental systems have recently provided evidence for HBx's properties in apoptosis (Chirillo et al., 1997; Kim et al., 1998; Oguey et al., 1996; Pollicino et al., 1998; Su and Schneider, 1997; Terradillos et al., 1998) . By contrast in other studies, HBx has been reported to inhibit apoptosis induced by p53 or by TGF-û (Elmore et al., 1997; Shih et al., 2000; Wang et al., 1995) , and HBx induction of NF-kB has been shown to promote cell survival (Pan et al., 2001; Su et al., 2001) . So far however, the precise mechanisms by which HBx interferes with the control of liver cell proliferation and apoptosis remain largely unknown.
Deregulation of apoptosis or programmed cell death is involved in a wide range of pathological processes, including autoimmune hepatitis, fulminant hepatitis and hepatocellular carcinoma (Galle et al., 1995; GraslKraupp et al., 1997; Kondo et al., 1997) . Apoptosis may be induced by diverse stimuli, notably by stimulation of Fas, a transmembrane receptor protein of the TNF receptor family (Nagata, 1997) . Fas is constitutively expressed in hepatocytes, and injection of an animal with agonistic anti-Fas antibodies causes immediate and massive apoptosis of hepatocytes, resulting in fulminant hepatitis and death, which can be blocked by liverspeci®c expression of Bcl-2 (Lachronique et al., 1996; Ogasawara et al., 1993) . Bcl-2 belongs to an evergrowing family of proteins that play a pivotal role in controlling apoptosis (for review, Adams and Cory, 1998) . Bcl-2 represses cell death by preventing insertion of Bax in the mitochondrial membrane and the following release of cytochrome c (Eskes et al., 2000; Kluck et al., 1997; Murphy et al., 1999; Yang et al., 1997) . It has been recently reported that Bcl-2 can block HBx-induced inhibition of focus formation (Kim et al., 1998; Schuster et al., 2000) .
In previous studies, we have shown that HBx expression in the mouse liver was reproducibly associated with increased hepatic apoptosis, and that HBx sensitized immortalized hepatocytes to Fasinduced cell death Terradillos et al., 1998) . In this report, we have investigated potential interactions of HBx with Bcl-2 during apoptosis triggered by Fas engagement in vivo. HBx transgenic mice were crossed with PK-hBcl-2 mice that are protected against Fas cytotoxicity by liver-speci®c expression of Bcl-2 (Lachronique et al., 1996) . No obvious change in the expression level or subcellular location of Bcl-2 could be evidenced in bitransgenic animals, and HBx did not interact with Bcl-2 in a yeast two-hybrid assay. However, in mice injected with agonistic anti-Fas antibodies, we demonstrate that HBx was able to abolish the protective eect of Bcl-2 and to restore sensitivity to the Fas signal leading to acute hepatic failure. This marked eect was associated with the ability of HBx to stimulate cytochrome c eux from mitochondria and cleavage of procaspase 3. Further studies in transiently transfected cells suggest that HBx induces alterations in the mitochondrial structure that may be related to its apoptotic activity.
Results
Contrasting effects of HBx and Bcl-2 on Fas-induced apoptosis in the transgenic liver HBx transgenic mice of the AX16 strain carrying the wild-type X gene of HBV have been described previously (Balsano et al., 1993; Billet et al., 1995) . In these animals, the HBx transgene is expressed at moderate levels in the neonatal liver and downregulated to extremely low levels in the adult liver, and the HBx protein is detectable only during the neonatal period (Terradillos et al., 1997) . We have previously shown that the hepatocyte turnover is stimulated in these mice, with slightly increased rates of cell death in the neonatal liver . To better de®ne the proapoptotic activity of HBx, we have tested the ability of this viral protein to interfere with the anti-apoptotic function of Bcl-2 in vivo. To this aim, heterozygous AX16 transgenic mice were crossed with PK-hBcl-2 mice which overexpress human Bcl-2 in the liver (Lachronique et al., 1996) . Four groups of animals were obtained: monotransgenic HBx and Bcl-2, bitransgenic HBx/Bcl-2, and nontransgenic mice. The 1.8 and 3.5 kb HBx-speci®c mRNAs were found to be produced at comparable levels in the livers of AX16 mice and AX16/PK-hBcl-2 animals by Northern blot analysis (data not shown). In a control experiment, spontaneous hepatic apoptosis was quanti®ed in untreated mice by in situ detection of DNA fragmentation (TUNEL assay). Con®rming previous observations , basal levels of TUNEL-positive cells ranged between 0.25% in non transgenic animals to 0.55% in HBx-expressing mice, and spontaneous apoptosis was also slightly elevated in PK-Bcl-2 livers (Table 1) . The anti-apoptotic activity of Bcl-2 was then assessed by injecting agonistic anti-Fas antibodies (Jo2) into neonates and adult animals.
Ten-day-old mice from the four groups (6 ± 8 animals in each group) were injected with the Fas antibody at 0.5 mg/kg. Because of the small size of neonates, we performed intraperitoneal injection. These experimental conditions were not lethal and the animals were sacri®ced 6 h post injection. At gross examination, the liver weight of HBx, HBx/Bcl-2 and nontransgenic mice was reduced of about 10% compared to that of untreated mice, while Jo2-injected Bcl-2 mice retained a normal liver mass (data not shown). Hepatocyte apoptosis was analysed on ®xed liver sections by in situ nick-end labeling of fragmented DNA (TUNEL assay) as described earlier . In line with previous reports (Lachronique et al., 1996; Rodriguez et al., 1996) , the rate of hepatocyte apoptosis was signi®cantly lower in hBcl-2 mice (11.6%) than in nontransgenic littermates (24.3%, P50.05) (Table 1) . Interestingly, the apoptotic indexes of monotransgenic HBx and bitransgenic HBx/Bcl-2 animals were similar to those of wild-type mice. In addition, examination of liver slides under phase contrast microscopy revealed more extensive morphological changes in the hepatocytes of HBx, HBx/Bcl-2 and nontransgenic mice than in the case of Bcl-2 mice (data not shown). Thus, the ability of Bcl-2 to inhibit hepatocyte death triggered by Fas engagement was impaired or bypassed in HBx transgenic mice.
We further analysed the role of HBx in adult animals, where HBx is expressed at barely detectable levels, by injecting the Fas-speci®c antibody Jo2 intravenously at 0.5 mg/kg into 2 to 3-month-old mice from the four groups. These conditions have been previously shown to be lethal for wild-type mice (Lachronique et al., 1996; Rodriguez et al., 1996) . In the present study, 70% of the nontransgenic animals succumbed within 5 h post injection and only 12.5% survived more than 48 h ( Figure 1 and Table 2 ). At autopsy, gross and histological studies of the livers revealed severe liver damage, peliosis and intraparenchymal hemorrhage. Similar results were obtained for the monotransgenic HBx mice, with slightly increased kinetics of death (average: 5.2 h versus 6.4 h for wild-type mice), but a slightly higher percentage of surviving mice. However, these dierences were not statistically signi®cant. Therefore, HBx expression had no signi®cant impact on hepatocyte sensitivity to Fas-induced apoptosis, both at moderate levels (neonates) and very low levels (adults). Analysis of monotransgenic Bcl-2 mice revealed, as expected, that a majority of animals survived anti-Fas injection (15/19, 79%) ( Figure 1 and Table 2 ). In striking contrast, most HBx/Bcl-2 mice (9/12, 75%) died within 48 h of injection. Fifty per cent of bitransgenic mice succumbed within 12 h post injection (T 50 =12 h) compared to 5 h for non-transgenics and 7 h for HBx mice (Table 2 ). For the nine deceased HBx/Bcl-2 mice, the death occurred later (about 10 h in average) than for monotransgenic HBx and non-transgenic mice. Most animals from all groups that survived at 48 h were still alive with a normal phenotype several weeks later. In summary, HBx expressed at low levels in adult HBx/Bcl-2 animals was able to restore sensitivity to fulminant liver destruction induced by Fas, although residual protection by Bcl-2 was inferred from the slightly delayed kinetics of death in bitransgenic animals.
Two-hybrid assay for HBx and Bcl-2 interactions
The ability of HBx to restore Fas-induced apoptosis in cells overexpressing Bcl-2 suggested that HBx might block Bcl-2 functions by a direct interfering binding. We used yeast two-hybrid assays to test this hypothesis. Both in Gal4 and LexA-based assays, HBx failed to interact with dierent members of the Bcl-2 family, including Bcl-2, Bcl-X L and Bax, while control experiments showed the expected binding of Bcl-2 with itself and with Bcl-X L and Bax (Table 3) . On the other hand, the interaction of HBx with the UV-damaged DNA-binding protein (UVDDB) was positive in both yeast systems, in agreement with previous reports (Lee et al., 1995; Sitterlin et al., 1997) . These data strongly suggest that HBx does not bind signi®cantly to either proapoptotic (Bax) or anti-apoptotic (Bcl-2, Bcl-X L ) members of the Bcl-2 family.
Expression and mitochondrial location of the hBcl-2 transgene are not modified by HBx
The observed sensitivity of HBx/Bcl-2 mice to anti-Fas antibody treatment prompted us to examine a putative action of HBx upon Bcl-2 expression, phosphorylation and subcellular localization. We ®rst evaluated the level of hBcl-2 transgene expression in Bcl-2 and HBx/Bcl-2 transgenic livers by Western blot analysis of total liver cell extracts, using a speci®c antibody to human Bcl-2. Similar, large amounts of human Bcl-2 protein were detected in liver extracts of Bcl-2 and HBx/Bcl-2 mice, as shown in Figure 2 (lanes 3 and 4) for 10-day-old animals. The observed doublet was due to a double translation start in the PK-hBcl-2 transgene construct (Lachronique et al., 1996) . The speci®city of hBcl-2 staining was con®rmed by the absence of signal in livers of nontransgenic or HBx mice (lanes 1, 2, 5 and 6). At 6 h after Jo2 inoculation in non-lethal conditions, the level and size of hBcl-2 protein remained unchanged both in Bcl-2 and HBx/Bcl-2 Results are expressed as the mean+s.d. Ntg, non transgenic C57B1/6 mice; n, number of animals in each group. *: Apoptotic rates were determined at 6 h after intraperitoneal injection of Fas antibodies in 10-day-old animals.
a : Similar rates of spontaneous apoptosis have been found in previous studies (Terradillos et al., 1998). b : Signi®cant at P50.05 Figure 1 Abrogation of the protective eect of Bcl-2 in HBx/ Bcl-2 transgenic mice after lethal injection of Fas antibody. The survival curves of 8 ± 12-week-old mice in response to a single intravenous injection of 10 mg of the anti-Fas antibody Jo2 are shown for each group. Animal numbers were as follows: nontransgenics (Ntg), n=16, HBx mice, n=8; Bcl-2 mice, n=19; HBx/Bcl-2 double transgenics, n=12. After 48 h, no further modi®cation of the survival pro®les was seen for any strain (Ojala et al., 2000) . In addition, we did not observe smaller fragments resulting from proteolytic degradation of Bcl-2 in bitransgenic livers. These results indicate that the viral regulatory protein HBx had no obvious eect on hBcl-2 transgene expression and Bcl-2 protein stability in hepatocytes from untreated and Jo2-treated mice. We next tested whether the subcellular localization of the transgenic hBcl-2 protein could be modi®ed by HBx. Liver slides from 10-day-old Bcl-2 and HBx/Bcl-2 mice were analysed by double immunostaining with antibodies against human Bcl-2 and mt-hsp-70, a protein constitutively expressed in the mitochondrial matrix. Similar punctuate cytosolic patterns corresponding to an extended peri-nuclear to cytoplasmic network were found with both antibodies by double immunostaining and confocal laser microscopy, indicating extensive mitochondrial localization of the Bcl-2 transgene in both strains (Figure 3) . No staining could be detected in the livers of HBx and nontransgenic mice with the anti-human Bcl-2 antibody (data not shown). After Fas antibody inoculation, a clear colocalization of Bcl-2 and hsp-70 was still observed in hepatocytes from Bcl-2 and HBx/Bcl-2 mice (data not shown). These results show that the association of Bcl-2 with mitochondria is not markedly disrupted in HBxexpressing. Because recent reports have localized HBx to the mitochondria (Rahmani et al., 2000; Takada et al., 1999) , the question of whether HBx co-localizes with Bcl-2 in a multiprotein complex at the mitochondrial membrane in our transgenic model is an interesting issue. However, the weak expression level of HBx in AX16 transgenic livers did not allow us to unambiguously localize the protein to a particular subcellular compartment.
HBx restores cytochrome c release and caspase 3 activation in Bcl-2 hepatocytes after Fas stimulation
It has been shown that Fas-induced apoptosis is associated with the release of cytochrome c from mitochondria to cytosol, and that cytochrome c release is blocked by Bcl-2 (Feldmann et al., 2000; Kluck et al., 1997) . We therefore investigated the subcellular distribution of cytochrome c in liver cells from Fasinoculated animals of the dierent strains. The percentages of apoptotic hepatocytes in these tissues are shown in Table 1 . Cytosolic and mitochondrialenriched fractions were prepared as previously described (Desagher et al., 1999) from total liver cells of 10-day-old mice, at 6 h after Jo2 injection. Correct fractionation was veri®ed by Western blotting with antibodies to cytosolic lactate dehydrogenase and mitochondrial hsp-70 (data not shown). Western blot analysis with anti-cytochrome c antibodies revealed partial cytochrome c release from mitochondria (HM fraction) into the cytosol (S fraction) in control nontransgenic livers (Figure 4a) . Importantly, cytochrome c was mainly localized in the cytosolic compartment of HBx and HBx/Bcl-2 transgenic hepatocytes, whereas it remained predominantly associated with the mitochondrial fraction in Bcl-2 transgenic mice.
We next analysed the cleavage of procaspase 3 precursor to its active form (Slee et al., 1999) . In Western blot experiments, the anti-caspase 3 antibody revealed both the precursor (p32) and the cleaved form (p17) in roughly equal amounts in liver from Jo2-injected nontransgenic animals (Figure 4b ). In Bcl-2 transgenic liver, the precursor form was predominant, but the 17 kDa active caspase 3 was clearly detected, probably re¯ecting the low percentage of apoptotic cells detected by the TUNEL assay (see Figure 1) . By contrast, in HBx 
In Gal4-based assays, the CG1945xY187 yeast diploid strain was cotransformed with plasmids expressing the Gal4 DNA-binding domain (GAl4BD) and the Gal4 activation domain (Gal4AD) fused to the indicated proteins. The LexA-based assay was performed in the L40 strain co-transformed with LexA/HBx and Gal4AD fused to the indicated proteins. Selected transformants were assayed for bgalactosidase activity. (+), positive within 1 h of incubation at 308C; (7), negative after overnight incubation. ND: not determined Figure 2 Western blot analysis of hBcl-2 transgene expression in mouse livers. Total liver extracts from 10-day-old untreated animals (lanes 1 ± 4) and at 6 h after injection of anti-Fas antibody (Fas Ab) (lanes 5 ± 8) were analysed for each strain by Western blotting with a monoclonal anti-human Bcl-2 antibody. Nontransgenic mice, lanes 1 and 5; HBx mice, lanes 2 and 6; Bcl-2 mice, lanes 3 and 7; HBx/Bcl-2 double transgenics, lanes 4 and 8. Loading of equal amounts of proteins was assessed by reprobing the blot with an anti-û-actin antibody. The presence of a speci®c Bcl-2 protein doublet in the livers of PK-hBcl-2 mice has been described previously (Lachronique et al., 1996) and HBx/Bcl-2 mice, the processing of caspase 3 was slightly increased compared to nontransgenic control. The ability of HBx to activate procaspase 3 cleavage was con®rmed in transient transfection assays. HeLa cells transfected with the pCMV-HBx expression vector or with the empty pCDNA3 vector were incubated with dierent doses of Fas antibodies. As shown in Figure 4c , the formation of the 17 kDa subunit of active caspase 3 was strongly increased in HBx-expressing cells after incubation with Fas antibodies. Moreover, the cleaved form of caspase 3 was also detected in HBx-transfected cells in the absence of antibody treatment, in agreement with our previous report . Thus, in Fas-induced apoptosis, HBx was shown to activate the translocation of cytochrome c and the cleavage of procaspase 3 in a way that cannot be prevented by Bcl-2.
Cytofluorometric detection of mitochondrial alterations in HBx-transfected cells
Cytochrome c eux from mitochondria has been associated with the formation of channels in the outer mitochondrial membrane through which cytochrome c diuses, together with other apoptotic proteins (Green and Reed, 1998) . To determine whether HBx-associated cytochrome c eux is associated with structural changes of the mitochondrial membrane, the immortalized mouse hepatocytes MMHD3 were transiently transfected with pCMV-HBx, together with a vector for the MHC class-I H2Kd cDNA as a membranous marker of positively transfected cells. Transfection with a FADD cDNA vector was used as a control. In a ®rst set of experiments, structural integrity of the mitochondrial membrane was assessed using the cardiolipinspeci®c¯uorescent dye 10N-nonyl-acridine orange (NAO) (Petit et al., 1995) . Apoptotic cells were labeled with 7-aminoactinomycin D (7-AAD) and harvested 48 h post transfection, as previously described (Terradillos et al., 1998). Cells were incubated with NAO for 30 min., ®xed in 1% PFA and analysed by¯ow cytometry. After gating with 7-AAD, NAO incorporation in apoptotic cells was strongly reduced compared to that of viable cells, both in HBx-and FADDtransfected cells (Figure 5a , upper panels). We then used the stable cationic¯uorophore dye CMXRos to evaluate changes in mitochondrial membrane potential (DC m ) (Macho et al., 1996) . At 48 h after transfection with pCMV-HBx or pFADD, MMHD3 cells were stained with chloromethyl-X-Rosamine (CMXRos) and FITC-conjugated anti-H2Kd antibodies. Flow cytometry analysis demonstrated decreased CMXRos staining in positively transfected cells, strongly suggesting a drop of DC m . Similar data were obtained in HeLa cells (data not shown). Because the decrease of NAO and CMXRos uorescence in HBx-transfected, apoptotic cells might be related to a reduction of global mitochondrial mass, we investigated the eect of ectopic expression of HBx on the level of expression of two mitochondrial proteins, cytochrome c oxydase II and mt-hsp 70. HeLa cells transfected with either pCMV-mycX or the empty pCDNA3 vector were harvested 48 h post transfection and cell lysates in Laemli buer were analysed by Western blot with cytochrome c oxydase II and mt-hsp70 monoclonal antibodies. The blots were also probed with anti-Myc antibodies to verify correct expression of Myc-tagged HBx, and with anti-PARP antibodies to con®rm execution of HBx-induced apoptosis (Figure 5b ). While the HBx protein was abundantly expressed and PARP was partially cleaved in HBx-transfected cells, no detectable change could be evidenced in the level of expression of cytochrome c oxydase II and mt-hsp70. These data indicate that structural alterations of the mitochondrial membrane 
Discussion
In this study, we have used transgenic mice that express HBx in hepatocytes at low, presumably relevant levels (Terradillos et al., 1997) , to investigate the activity of the viral protein in the context of Fas-mediated liver damage. Mice were exposed to Fas antibodies, either at a dose known to induce lethal hepatic failure in wild-type animals (Ogasawara et al., 1993) or at a sublethal dose. The response of HBx monotransgenic mice to Fas stimulation was roughly comparable to that of wild-type littermates, both by the rate of apoptotic hepatocytes and by the sensitivity to Fas killing. Previous studies in dierent established cell lines have reported opposite eects of HBx in either inhibition or potentiation of Fasmediated apoptosis (Diao et al., 2001; Pan et al., 2001; Terradillos et al., 1998) . It is possible that HBx expression levels, availability of survival versus apoptogenic factors, and experimental setting might profoundly aect the fate of cells exposed to Fas stimulation. The exquisite sensitivity of hepatocytes to Fas-mediated apoptosis in vivo has been related to high basic While Bcl-2 is barely detectable in human and animal hepatocytes, overexpression of Bcl-2 in transgenic livers can block Fas-induced apoptosis (Lachronique et al., 1996; Rodriguez et al., 1996) . Based on the resistance of Bcl-2 and Bcl-x L transgenic mice to Fas cytotoxicity, hepatocytes resemble type II cells in which Fas-induced apoptosis is dependent on a mitochondrial`ampli®er' function (de la Coste et al., 1999; Scadi et al., 1998; Yin et al., 1999) . In this type of cells, caspase 8-mediated cleavage of Bid and mitochondrial translocation of tBid induce mitochondrial damage and leakage of cytochrome c, which in turn triggers irreversible activation of caspases 8, 9 and 3 (Feldmann et al., 2000; Li et al., 1998; Slee et al., 1999) .
Here we show that HBx acutely sensitized resistant hBcl-2 transgenic mice to Fas-induced liver damage. It is remarkable that HBx expressed at very low levels exerted a dominant function in the presence of high levels of Bcl-2. The inability of Bcl-2 to protect HBxexpressing hepatocytes against Fas cytotoxicity might result either from inactivation of Bcl-2 or from execution of a Bcl-2-independent death pathway. In the present study, none of the strategies used by other viral proteins to inactivate Bcl-2 could be evidenced, including down-regulation of Bcl-2 expression, proteolytic cleavage and probably also phosphorylation of the Bcl-2 protein (Aillet et al., 1998; Grandgirard et al., 1998; Ojala et al., 2000) . Furthermore, HBx did not apparently modify the subcellular localization of the hBcl-2 protein. Finally, the lack of interaction between HBx and Bcl-2 in yeast two-hybrid assays and the huge dierence between HBx and Bcl-2 protein levels do not favor inactivation via direct interfering binding. Alternatively, HBx might activate the execution of Fas apoptosis in a way that cannot be prevented by Bcl-2. We show that cytochrome c release from mitochondria and caspase 3 processing triggered by Fas were eciently blocked in Bcl-2 transgenic livers, but these apoptotic steps were restored to normal levels in HBx/Bcl-2 livers. Moreover, our data in transiently transfected cells support the notion that HBx might trigger mitochondrial membrane alterations rather than global changes in mitochondrial mass. Thus, HBx could bypass the Bcl-2 checkpoint that regulates eux of cytochrome c into the cytosol. A direct interaction of HBx with the mitochondrial membrane has been supported by recent studies showing that HBx localizes to the mitochondria (Takada et al., 1999) and alters DCm via interaction with the voltage-dependent anion channel VDAC3 (Rahmani et al., 2000) . Bcl-2 family proteins bind to VDAC to regulate the release of cytochrome c; therefore, it is tempting to speculate that VDAC3-HBx interactions might induce conformational changes that abolish the modulation of channel activity by Bcl-2. It is also conceivable that HBx might counteract Bcl-2 by activating the expression of a natural inhibitor such as Bax or a BH3-only Bcl-2 family member. Because HBx can presensitize cells to apoptotic signals acting via dierent molecular triggers, it probably acts at a common node regulating various apoptotic pathways (Bergametti et al., 1999; Chirillo et al., 1997; Kim et al., 1998; Sirma et al., 1998 Sirma et al., , 1999 Terradillos et al., 1998) . Our data suggest that the release of mitochondrial cytochrome c might account for HBx apoptotic function, as proposed recently for cMyc (Juin et al., 1999) .
In chronic HBV infection, liver cell injury is thought to be mediated mostly by the cellular immune response, but there is increasing evidence that the HBx protein interacts with regulatory pathways controlling apoptosis. The hypothesis that HBx might play a role as à sensitizer' to other pro-apoptotic stimuli has been notably supported by its ability to increase cell sensitivity to apoptotic death induced by TNF-a, a pro-in¯amma-tory cytokine implicated in chronic liver diseases (Spengler et al., 1996; Schneider, 1997, Su et al., 2001) . In the present work, we have demonstrated that HBx exerts a dominant proapoptotic eect over Bcl-2-regulated control of apoptosis in vivo. Recently, it has been shown that HBx ampli®es TGF-û signaling through direct interaction with Smads, suggesting a role of the viral protein in HBV-associated liver ®brosis (Lee et al., 2001) . At tumoral stages, downregulation of Fas expression (Strand et al., 1996) , as well as loss of apoptotic activity of HBx mutants (Sirma et al., 1999; Yeh et al., 2000) might be important steps in the escape of tumor cells from apoptosis.
Materials and methods

Transgenic mice and treatments
The generation of AT3-HBx and PK-hBcl-2 transgenic mice has been described previously (Balsano et al., 1993; Billet et al., 1995; Lachronique et al., 1996) . In the AX16 line, the X gene of HBV was inserted downstream of the anti-thrombin III promoter. HBx expression levels in the liver declined as the animals aged until barely detectable in adults (Terradillos et al., 1997) . The nucleotide sequence of the X transgene (HBV subtype ayw) (Galibert et al., 1979) was veri®ed at regular intervals and remained unchanged over generations. The human bcl-2 cDNA transgene controlled by the Lpyruvate kinase (PK) promoter was abundantly expressed in the liver (Lachronique et al., 1996) . These lines were maintained by breeding to C57B1/6 inbred mice under pathogen-free conditions. Animal care and sacri®ce were performed according to the EEC guidelines.
Heterozygous HBx and hBcl-2 animals were crossed to generate an experimental cohort including single HBx and Bcl-2 transgenic, bitransgenic and nontransgenic animals. A puri®ed hamster monoclonal anti-murine Fas antibody (Jo2, Pharmingen) was injected either intraperitonally (i.p.) into 10-day-old mice or intravenously (i.v.) into 2 to 3-monthold animals at 0.5 mg/kg in 100 ml sterile saline. Although the same Jo2 dosage was used in neonates and adults, the i.v. injection was lethal in adult wild-type animals, while the i.p. injection in neonates was not. Ten-day-old mice were sacri®ced 6 h after inoculation and the livers were excised. Liver fragments were processed for subcellular fractionation, total protein analysis, or in situ detection of apoptosis by immunohistochemical labeling. After lethal challenge, adult animals were examined with mortality as the end point.
Antibodies and reagents
The mouse monoclonal anti-human Bcl-2 antibody (clone 124) was purchased from DAKO S.A. (Trappes, France). The mouse monoclonal antibody raised against human, mouse, and rat cytochrome c, the rabbit polyclonal anti-caspase 3 antibody that recognizes both the 32 kDa procaspase and its 17 kDa derivative, and the monoclonal anti-PARP antibody were from Pharmingen (San Diego, CA, USA). The mouse monoclonal antibodies against mitochondrial heat shock protein 70 (mt-hsp-70) and human Fas (CD95) were purchased respectively from ABR (Laufel®ngen, Switzerland) and Chemicon (Temecula, CA, USA). Polyclonal antibodies to lactate dehydrogenase (LDH4) were from Anawa (ZuÈ rich, Switzerland). Monoclonal antibodies speci®c for c-Myc (clone 9E10), cytochrome c oxydase II and û-actin were from Santa-Cruz Biotechnology (Santa-Cruz, CA, USA), Molecular Probes and Sigma-Aldrich (Saint-Quentin, France), respectively.
In situ detection of apoptosis
Liver tissues were ®xed in 4% paraformaldehyde, embedded in paran and cut at 5 mm. Liver cells undergoing apoptosis were labeled by in situ nick-end labeling of nucleosomal DNA (TUNEL) as described previously (Terradillos et al., 1997) . Apoptotic scores are shown as the mean of per cent apoptotic hepatocytes in each of 20 consecutive optic ®elds (6400, 150 hepatocytes per ®eld).
Immunofluorescence microscopy
Indirect immuno¯uorescent staining for Bcl-2 and HSP 70 was performed on ®xed, paran-embedded liver sections as described previously (Lachronique et al., 1996) . In brief, after antigen retrieval by microwave oven heating (265 min in citrate buer 10 mM pH 6), non speci®c sites were saturated with blocking buer (LSAB kit, DAKO). Slides were incubated with primary antibodies for 1 h at room temperature, washed with PBS, and incubated with appropriate secondary antibodies conjugated with either¯uorescein or Texas red (Tropix, Foster City, CA, USA), for 30 min at room temperature. Slides were washed extensively with PBS and mounted with coverslips in Vectashield mounting medium (Vector). Single and doublestained liver sections were observed using a laser scanning confocal microscope Leica TCS 4D.
Cell culture and transfections
HeLa cells (ATCC-CC1) and MMHD3, a well-dierentiated murine hepatocyte cell line (Amicone et al., 1997) , were grown in RPMI 1640 (Gibco, BRL) containing 10% fetal calf serum, with 5% CO2 at 378C. HeLa cells were transfected with either the pCMV-mycX vector for Myc-tagged HBx or empty pCDNA3 (4 mg) by calcium phosphate precipitation. Cells were harvested at 48 h after transfection, washed in PBS, lyzed in Laemli buer and cell lysates were analysed by Western blotting with various antibodies. Alternatively, at 24 h post transfection, cells were incubated with dierent concentrations of monoclonal antihuman Fas antibody, harvested after 6 h, and tested for activation of caspase 3 by Western blotting. MMDH3 cells were grown at 30% con¯uency in 10-cm collagen-coated dishes and co-transfected with 10 mg of pCMV-mycX or the empty pCDNA3 vector and 3 mg of MHC class I H2Kd vector (pH2Kd) by calcium phosphate precipitation.
Preparation of liver cell extracts, subcellular fractionation and Western blotting
Frozen liver tissues were thawed in isotonic mitochondrial buer and homogenized with a Dounce homogenizer. After centrifugation at 500 g for 5 min at 48C, enriched cytosolic and heavy membrane (mitochondrial) fractions were prepared as described previously (Desagher et al., 1999) . Proteins were separated by SDS ± PAGE on 4 ± 20% Tris-Glycine gels (NOVEX, Groningen, The Netherlands). After transfer to a nitrocellulose membrane and blocking nonspeci®c sites with 5% non-fat milk and 0.2% Tween 20 in PBS, membranes were incubated overnight at 48C with anti-cytochrome c (dilution: 1 : 2500) or anti-caspase 3 antibodies (dilution: 1 : 2000). Equal loading of the samples and transfer were veri®ed using antibodies to lactate dehydrogenase (LDH) and mitochondrial HSP-70. Blots were incubated with the appropriate peroxydase-conjugated secondary antibodies, washed extensively, and enhanced chemiluminescence reagents (ECL, Amersham) were used for detection.
Flow cytometry analysis
MMHD3 cells at 30% con¯uency in 10-cm dishes were cotransfected with pCMV-HBx (10 mg) and a MHC class-I H2Kd vector (pH2Kd) (3 mg). In control experiments, cells were transfected with either the empty pCDNA3 vector, or with a vector for human FADD cDNA (pcDNA3-AU1-FADD) (Chinnaiyan et al., 1995) , together with pH2Kd. After 48 h, adherent and¯oating cells were harvested and apoptosis in transfected cells was quantitated by incubating cells with 20 mg/ml 7-aminoactinomycin D (7-AAD, Sigma) for 30 min at 48C in the dark (Lecoeur and Gougeon, 1996) . To evaluate alterations of mitochondrial structural integrity, 7-AAD stained cells were incubated in 200 ml of PBS containing 8 mM of 10-N-nonyl-3,6-bis [dimethylamino] acridine (NAO) for 30 min, as described previously (Petit et al., 1995) . Cells were ®xed in 1% PFA and analysed in a FACScan (Becton Dickinson)¯ow cytometer as described previously . After¯ow cytometry analysis, data from 10 000 events were registrated in logarithmic scale and analysed using Cell Quest software. To evaluate loss of mitochondrial transmembrane potential (DC m ) in the positively transfected cells, cells were incubated with FITC-conjugated anti-H2Kd antibodies (Pharmingen) at 48C for 45 min. in the presence of 150 nM chloromethyl-Xrosamine (CMXRos) (Molecular Probes) (Macho et al., 1996) . Cells were analysed by¯ow cytometry as above.
Yeast two-hybrid assays
For Gal4-based two-hybrid assay, the full-length cDNAs of Bcl-2, Bcl-X L and Bax (kindly supplied by P Barr, LXR Biotechnology, Richmond, CA, USA) and the HBx gene were cloned into the pActII vector (Harper et al., 1993) and pAs2DD vector (Flajolet et al., 2000) . Details of the constructs are available upon request. Plasmids carrying the cDNAs of the Prp21 splicing factor and UV-Damaged DNA-Binding protein (UVDDB) have been described previously (Sitterlin et al., 1997) . The CG1945xY187 yeast diploid strain (Flajolet et al., 2000) was co-transformed with various combinations of these constructs as indicated in Table 3 . The resulting transformants were screened for growth on SD plate medium lacking tryptophan and leucine. Selected colonies were assayed for û-galactosidase reporter activity, using a previously described colorimetric assay (Transy and Legrain, 1995) . For LexAbased assays, the HBx gene was cloned in the pBMT16 vector. The L40 yeast haploid strain was co-transformed by the pActII and pBMT16-based plasmids expressing Bcl-2 family members and HBx, respectively (Hollenberg et al., 1995) .
Data analysis
Between-group comparisons were performed with the nonparametric Mann ± Whitney tests. Probability levels less than 0.05 (P50.05) were considered signi®cant.
